Background It has been reported that people with COVID‐19 and pre‐existing
autoantibodies against type I interferons are likely to develop an inflammatory cytokine storm …

Despite global vaccination programs, infections with severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) continue to cause severe disease with significant morbidity …

Objective Randomized controlled trials comparing tocilizumab and baricitinib in patients with
coronavirus disease 2019 (COVID-19) are needed. This was an open-label, randomized …

Clinical outcomes from infection with SARS-CoV-2, the cause of the COVID-19 pandemic,
are remarkably variable ranging from asymptomatic infection to severe pneumonia and …

Abstract The coronavirus disease 2019 (COVID-19) pandemic has been a serious threat to
global health for nearly 3 years. In addition to pulmonary complications, liver injury is not …

Background Elevated levels of inflammatory factors are associated with poor prognosis in
coronavirus disease-19 (COVID-19). However, mesenchymal stem cells (MSCs) have …

Background A recent prospective meta-analysis demonstrated that interleukin-6 antagonists
are associated with lower all-cause mortality in hospitalised patients with COVID-19 …

Objective: This review was performed to compare the efficacy and safety among hospitalized
patients with COVID-19 who received baricitinib and those who received tocilizumab …

Aim Many randomized controlled trials (RCTs) have investigated the use of interleukin 6
antagonists for the treatment of coronavirus disease 2019 (COVID‐19), yielding inconsistent …

SARS-CoV-2 infection can produce a variety of clinical manifestations, which are either
directly related to viral tissue damage or indirectly induced by the antiviral immune …